Susanne Behlke

Med’Inn’Pharma (MIP) is a pre-clinical stage Biotech with the mission to develop a new generation of human cell-derived therapeutics with truly disease modifying properties.

We use our propriatery platform to induce human cells to release desired bioactive molecules that we transform into stable biologic drug products. Our first candidates issued from that platform are dedicated to actively resolve pathologic inflammation without suppressing the immune system. By targeting an universal mechanism of regeneration, our candidates are applicable to a wide range of degenerative diseases and conditions intended cure disease and improve health span.

Currently, our priority is to generate clinical proof of concept trials through both autologous self-resolutome & pro-resolutive drug candidate programs.